Receptor News and Research

RSS

Promising immunotherapy uses cancer-killing cells to destroy malignant tumors

Researchers at McMaster University have developed a promising new cancer immunotherapy that uses cancer-killing cells genetically engineered outside the body to find and destroy malignant tumors.

28 Jun 2021

Antagonism of glucocorticoid receptors promotes apoptosis in solid tumor cells

Oncotarget published "Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells" which reported that to guide studies in cancer patients, relacorilant, an investigational selective GR modulator that antagonizes cortisol activity, was assessed in various tumor types, with multiple cytotoxic combination partners, and in the presence of physiological cortisol concentrations.

28 Jun 2021

Study explores the potential role of gene polymorphisms in pathogenesis of prostate cancer

Oncotarget published "The presence of polymorphisms in genes controlling neurotransmitter metabolism and disease prognosis in patients with prostate cancer: a possible link with schizophrenia" reported that polymorphisms of neurotransmitter metabolism genes were studied in patients with prostate cancer (PC) characterized by either reduced or extended serum prostate-specific antigen doubling time corresponding to unfavorable and favorable disease prognosis respectively.

28 Jun 2021

Tocilizumab and sarilumab shown to be effective in critical COVID-19

A new study, released as a preprint on the medRxiv* server, describes how a team of researchers from the University Medical Center Utrecht in the Netherlands explored the efficacy of four monoclonal antibodies that antagonize powerful pro-inflammatory pathways. The team sought to determine which were useful in treating critically ill COVID-19 patients on organ support.

28 Jun 2021

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

A recent study conducted by an international team of scientists has revealed that the Oxford-AstraZeneca coronavirus disease 2019 (COVID-19) vaccine, AZD1222, is capable of inducing strong spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses in vaccinated individuals. A detailed description of AZD1222-induced cellular immunity is currently available on the medRxiv* preprint server.

28 Jun 2021

Why SARS-CoV-2 delta variant is more infectious

German experts recently explained why the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant is more infectious and pathogenic than its ancestor. By conducting a series of in vitro experiments, they have revealed that increased ability to induce cell-to-cell fusion (syncytia) and reduced susceptibility to vaccine and infection-induced antibodies make the delta variant more infectious than previously circulating variants. The study is currently available on the bioRxiv* preprint server.

28 Jun 2021

Swedish study reveals how long immunity lasts after mild COVID

As a result of the ongoing pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, the coronavirus disease 2019 (COVID-19), the global public health at risk has never been more dire.

27 Jun 2021

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine.

27 Jun 2021

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Researchers have described the first reported infection with the C.37 (Lambda) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Southern Brazil.

27 Jun 2021

New insights on how an important class of immune receptors are activated

Scientists from within the Antibody and Vaccine Group at the University of Southampton have gained novel insights into how an important class of immune receptors called tumour necrosis factor receptors (TNFR) are activated.

25 Jun 2021

Mayo Clinic researchers are working toward new CAR-T cell treatment for multiple myeloma

Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma.

25 Jun 2021

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Even as herculean efforts are being made to extend the reach of vaccination against COVID-19 to all the regions of the world, there is a dire need for rapid and sensitive tests to assess the antibody response to the various vaccines used and to monitor antibody titers over time. A new preprint describes a new approach to this problem which could be applied to other molecules of interest as well, both in laboratories and at the point of care.

25 Jun 2021

Mutations in HER2 gene can spur tumor growth in breast cancer

Mutations in a gene related to HER2, a gene frequently implicated in breast cancers and a variety of other malignancies, can amplify activity that spurs tumor growth, a new study led by UT Southwestern researchers suggests.

25 Jun 2021

Study shows how SARS-CoV-2 virus enters cells to cause infection

Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection.

24 Jun 2021

Researchers develop a low-cost automated rapid test for detecting SARS-CoV-2 antibodies

During the continued progression of the Corona pandemic, rapid, inexpensive, and reliable tests will become increasingly important to determine whether people have the associated antibodies - either through infection or vaccination.

24 Jun 2021

City of Hope researchers identify how breast cancer cells acquire resistant traits

City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer.

24 Jun 2021

Scientists predict driver mutations of future SARS-CoV-2 variants of concern

A team of scientists from the USA has recently predicted the driver mutations that may appear in future variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The prediction is based on currently available genetic surveillance data on amino acid mutations present in SARS-CoV-2 variants. A detailed description of the study is currently available on the medRxiv* preprint server.

24 Jun 2021

SARS-CoV-2 causes ER-stress-activated unfolded protein response leading to cell death

A new study describes the varying ways in which the virus co-opts the machinery of the host cell following infection to evade or modulate the host immune response, alter the pattern of translation of viral proteins, and the release of new viral particles.

24 Jun 2021

New insights can pave the way for targeted therapies to fight blood clots in COVID-19 patients

Driven by the mystery of the blood clots reported in both living and deceased COVID-19 patients, researchers from Shoolini University, India, dig deeper into the pathogenesis of COVID-19 and other similar viral diseases, looking for ways in which these clots could be formed.

24 Jun 2021

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

A team of UK-based scientists has developed and validated a DNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that encodes both spike receptor-binding domain (RBD) and nucleocapsid of the virus as vaccine immunogens.

24 Jun 2021

Receptor News and Research

Promising immunotherapy uses cancer-killing cells to destroy malignant tumors

Antagonism of glucocorticoid receptors promotes apoptosis in solid tumor cells

Study explores the potential role of gene polymorphisms in pathogenesis of prostate cancer

Tocilizumab and sarilumab shown to be effective in critical COVID-19

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

Why SARS-CoV-2 delta variant is more infectious

Swedish study reveals how long immunity lasts after mild COVID

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

New insights on how an important class of immune receptors are activated

Mayo Clinic researchers are working toward new CAR-T cell treatment for multiple myeloma

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Mutations in HER2 gene can spur tumor growth in breast cancer

Study shows how SARS-CoV-2 virus enters cells to cause infection

Researchers develop a low-cost automated rapid test for detecting SARS-CoV-2 antibodies

City of Hope researchers identify how breast cancer cells acquire resistant traits

Scientists predict driver mutations of future SARS-CoV-2 variants of concern

SARS-CoV-2 causes ER-stress-activated unfolded protein response leading to cell death

New insights can pave the way for targeted therapies to fight blood clots in COVID-19 patients

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News